Skip to main content
Top
Published in:

Open Access 01-12-2023 | Neurofibromatosis | Research

Risk factors for intraoperative hemorrhage of Type I neurofibromatosis

Authors: Qianqian Gao, Siwei Qu, Ning Ma, Weixin Wang, Sen Chen, Zhe Yang, Yangqun Li

Published in: BMC Surgery | Issue 1/2023

Login to get access

Abstract

Introduction

Neurofibromatosis (NF) is an inherited disease and a benign tumor originating from nerve sheath cells. Neurofibromatosis type I (NF1) is the most common type, and most cases are characterized by neurofibromas. Neurofibromas in NF1 are mainly treated by surgery. Our study explores the risk factors for intraoperative hemorrhage in Type I neurofibromatosis patients who underwent neurofibroma resection.

Methods

A cross-sectional comparison of the patients who had undergone resection of neurofibroma for NF1. Data regarding patient characteristics and data about operative outcomes were recorded. The definition of intraoperative hemorrhage group was the intraoperative blood loss greater than 200 ml.

Results

Of 94 eligible patients, 44 patients were in the hemorrhage group and 50 patients were in the non-hemorrhage group. Multiple logistic regression analysis demonstrated that the area of excision, classification, surgical site, primary surgical, and organ deformation were significant independent predictors of hemorrhage.

Conclusion

Early treatment can reduce the tumor cross-sectional area, avoid organ deformation, and reduce intraoperative blood loss. For plexiform neurofibroma or neurofibroma of the head and face, the amount of blood loss should be predicted correctly, and preoperative evaluation and blood preparation should be paid more attention to.
Literature
1.
go back to reference Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S. An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol. 2020;139(4):643–65.CrossRefPubMed Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S. An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol. 2020;139(4):643–65.CrossRefPubMed
2.
go back to reference Evans DG, Bowers NL, Tobi S, Hartley C, Wallace AJ, King AT, et al. Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry. 2018;89(11):1215–9.CrossRefPubMed Evans DG, Bowers NL, Tobi S, Hartley C, Wallace AJ, King AT, et al. Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry. 2018;89(11):1215–9.CrossRefPubMed
3.
go back to reference Nix JS, Blakeley J, Rodriguez FJ. An update on the central nervous system manifestations of neurofibromatosis type 1. Acta Neuropathol. 2020;139(4):625–41.CrossRefPubMed Nix JS, Blakeley J, Rodriguez FJ. An update on the central nervous system manifestations of neurofibromatosis type 1. Acta Neuropathol. 2020;139(4):625–41.CrossRefPubMed
5.
go back to reference Wang W, Wei CJ, Cui XW, Li YH, Gu YH, Gu B, et al. Impacts of NF1 gene mutations and genetic modifiers in neurofibromatosis Type 1. Front Neurol. 2021;12:704639.CrossRefPubMedPubMedCentral Wang W, Wei CJ, Cui XW, Li YH, Gu YH, Gu B, et al. Impacts of NF1 gene mutations and genetic modifiers in neurofibromatosis Type 1. Front Neurol. 2021;12:704639.CrossRefPubMedPubMedCentral
6.
go back to reference Ozarslan B, Russo T, Argenziano G, Santoro C, Piccolo V. Cutaneous findings in neurofibromatosis Type 1. Cancers (Basel). 2021;13(3):463.CrossRefPubMed Ozarslan B, Russo T, Argenziano G, Santoro C, Piccolo V. Cutaneous findings in neurofibromatosis Type 1. Cancers (Basel). 2021;13(3):463.CrossRefPubMed
7.
8.
go back to reference Landry JP, Schertz KL, Chiang YJ, Bhalla AD, Yi M, Keung EZ, et al. Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020. JAMA Netw Open. 2021;4(3):210495.CrossRef Landry JP, Schertz KL, Chiang YJ, Bhalla AD, Yi M, Keung EZ, et al. Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020. JAMA Netw Open. 2021;4(3):210495.CrossRef
9.
go back to reference Lasater EA, Li F, Bessler WK, Estes ML, Vemula S, Hingtgen CM, et al. Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans. J Clin Invest. 2010;120(3):859–70.CrossRefPubMedPubMedCentral Lasater EA, Li F, Bessler WK, Estes ML, Vemula S, Hingtgen CM, et al. Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans. J Clin Invest. 2010;120(3):859–70.CrossRefPubMedPubMedCentral
10.
go back to reference Fisher MJ, Blakeley JO, Weiss BD, Dombi E, Ahlawat S, Akshintala S, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 2022;24(11):1827–44.CrossRefPubMedPubMedCentral Fisher MJ, Blakeley JO, Weiss BD, Dombi E, Ahlawat S, Akshintala S, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 2022;24(11):1827–44.CrossRefPubMedPubMedCentral
11.
go back to reference Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988;111(Pt 6):1355–81.CrossRefPubMed Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988;111(Pt 6):1355–81.CrossRefPubMed
12.
go back to reference Farschtschi S, Mautner VF, McLean ACL, Schulz A, Friedrich RE, Rosahl SK. The neurofibromatoses. Dtsch Arztebl Int. 2020;117(20):354–60.PubMedPubMedCentral Farschtschi S, Mautner VF, McLean ACL, Schulz A, Friedrich RE, Rosahl SK. The neurofibromatoses. Dtsch Arztebl Int. 2020;117(20):354–60.PubMedPubMedCentral
13.
go back to reference National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. Neurofibromatosis. 1988;1(3):172-8. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. Neurofibromatosis. 1988;1(3):172-8.
14.
go back to reference Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834–43.CrossRefPubMed Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834–43.CrossRefPubMed
15.
go back to reference Charest M, Pressacco J, Thomas-Gittens J. Malignant peripheral nerve sheath tumours of the pericardium in a patient with Neurofibromatosis type 1: The diagnostic value of 18F-FDG PET-CT and I-123 MIBG SPECT-CT. J Nucl Med Technol. 2018;46(1):61-2. Charest M, Pressacco J, Thomas-Gittens J. Malignant peripheral nerve sheath tumours of the pericardium in a patient with Neurofibromatosis type 1: The diagnostic value of 18F-FDG PET-CT and I-123 MIBG SPECT-CT. J Nucl Med Technol. 2018;46(1):61-2.
16.
go back to reference Salma RG, Al-Shammari FM, Al-Garni BA, Al-Qarzaee MA. Operative time, blood loss, hemoglobin drop, blood transfusion, and hospital stay in orthognathic surgery. Oral Maxillofac Surg. 2017;21(2):259–66.CrossRefPubMed Salma RG, Al-Shammari FM, Al-Garni BA, Al-Qarzaee MA. Operative time, blood loss, hemoglobin drop, blood transfusion, and hospital stay in orthognathic surgery. Oral Maxillofac Surg. 2017;21(2):259–66.CrossRefPubMed
17.
go back to reference Seruya M, Oh AK, Rogers GF, Han KD, Boyajian MJ, Myseros JS, et al. Blood loss estimation during fronto-orbital advancement: implications for blood transfusion practice and hospital length of stay. J Craniofac Surg. 2012;23(5):1314–7.CrossRefPubMed Seruya M, Oh AK, Rogers GF, Han KD, Boyajian MJ, Myseros JS, et al. Blood loss estimation during fronto-orbital advancement: implications for blood transfusion practice and hospital length of stay. J Craniofac Surg. 2012;23(5):1314–7.CrossRefPubMed
18.
go back to reference Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123(1):124–33.CrossRefPubMed Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123(1):124–33.CrossRefPubMed
19.
go back to reference Jouhilahti EM, Peltonen S, Callens T, Jokinen E, Heape AM, Messiaen L, et al. The development of cutaneous neurofibromas. Am J Pathol. 2011;178(2):500–5.CrossRefPubMedPubMedCentral Jouhilahti EM, Peltonen S, Callens T, Jokinen E, Heape AM, Messiaen L, et al. The development of cutaneous neurofibromas. Am J Pathol. 2011;178(2):500–5.CrossRefPubMedPubMedCentral
20.
go back to reference Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol. 2007;6(4):340–51.CrossRefPubMed Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol. 2007;6(4):340–51.CrossRefPubMed
21.
go back to reference Kwon JY, Byun JH, Shin I, Hong S, Kim R, Park IY. Risk factors for intraoperative hemorrhage during cesarean myomectomy. Taiwan J Obstet Gynecol. 2021;60(1):41–4.CrossRefPubMed Kwon JY, Byun JH, Shin I, Hong S, Kim R, Park IY. Risk factors for intraoperative hemorrhage during cesarean myomectomy. Taiwan J Obstet Gynecol. 2021;60(1):41–4.CrossRefPubMed
Metadata
Title
Risk factors for intraoperative hemorrhage of Type I neurofibromatosis
Authors
Qianqian Gao
Siwei Qu
Ning Ma
Weixin Wang
Sen Chen
Zhe Yang
Yangqun Li
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Surgery / Issue 1/2023
Electronic ISSN: 1471-2482
DOI
https://doi.org/10.1186/s12893-023-02067-7

Other articles of this Issue 1/2023

BMC Surgery 1/2023 Go to the issue
SPONSORED

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

  • Webinar | 06-02-2024 | 20:00 (CET)

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by:
  • Viatris
Developed by: Springer Healthcare
Watch now